Minhua Han

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Simon C Watkins, D. Davar, Joe-Marc Chauvin, 2022, The Journal of clinical investigation.

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

A. Korman, R. Johnston, M. Quigley, 2016, PloS one.

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

A. Korman, R. T. Bunch, M. Selby, 2014, Cancer Immunology Research.

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

A. Korman, R. Johnston, M. Quigley, 2016, PloS one.

Antibodies to Modulate Surface Receptor Systems Are Often Bivalent and Must Compete in a Two‐Dimensional Cell Contact Region

Yougan Cheng, T. Leil, D. Tenney, 2019, CPT: Pharmacometrics & Systems Pharmacology.

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

A. Korman, M. Selby, Susan Wong, 2014, Cancer Immunology Research.